Not a news release, butone he11uva Letter to Shareholders. Looks like the reason Genenews has been static for awhile is because they have been building a monster infrastructure to launch GEN into the stratosphere. Last year all (!) GEN had was an enthusiastic client base and a growing list of outstanding genetic pin-prik blood tests (prostate, breast, lung, colon...) that predicted cancer earlier and more effectively than anything out there (eg. Their breast cancer test is not affected by breast density). It appears Tripp has been hard at it: - Genenews is a significant part of the MyCancerRisk program that monitors high-risk
populations - They are working with JTS Healthcare partners to launch programs with multiple hospitals and clinics across 5 states in first Q 2018 - they are ramping up their Telemedicine program to electronically give access to physicians and patients to 8000 draw-sites and electronic payment - they are continuing cancer research to expand their already robust database showing the effectiveness of GEN tests in early cancer diagnosis and therefore more effective, in both cost and health, treatment - very useful when presenting to large healthcare providers. - this in addition to continued growth (and improved billing practices) in small clinics. - Tripp identifies 4 main revenue streams: High risk patients, Telemedicine, Large healthcare systems, Small clinical practices Call me crazy, but the future looks bright. Next up, signed, large healthcare contracts. Don't go by my summary - the letter is worth a read. Follow the link.
GENENEWS Letter to Shareholders https://www.newswire.ca/news-releases/genenews-announces-letter-to-shareholders-from-ceo-668134843.html